Strides Shasun gets tentative USFDA nod for Roflumilast tablets
NEW DELHI: Strides Shasun has received tentative approval from the US health regulator for Roflumilast tablets, used for the treatment of inflammatory conditions of the lungs.
The company has received tentative approval from the US Food and Drug Administration (USFDA) for Roflumilast tablets 500 mcg, Strides Shasun said in a BSE filing.
The product has received approval in 15 months under the USFDA's new product clearance regime of GDUFA. The product can be launched earliest by January 2020, it added.
According to IMS sales data, the US market for Roflumilast tablets 500 mcg is around $ 174 million.
The company will manufacture the product at its oral dosage facility in Bengaluru.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd